Home LiteratureArticle Details
PMID: 12750401 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

The Journal of clinical investigation ·Vol. 111 ·No. 10 ·2003-05-00 ·Pages 1519-27

Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P

Abstract

Chronic hypoxia induces pulmonary vascular remodeling, leading to pulmonary hypertension, right ventricular hypertrophy, and heart failure. Heterozygous deficiency of hypoxia-inducible factor-1alpha (HIF-1alpha), which mediates the cellular response to hypoxia by increasing expression of genes involved in erythropoiesis and angiogenesis, has been previously shown to delay hypoxia-induced pulmonary hypertension. HIF-2alpha is a homologue of HIF-1alpha and is abundantly expressed in the lung, but its role in pulmonary hypertension remains unknown. Therefore, we analyzed the pulmonary response of WT and viable heterozygous HIF-2alpha-deficient (Hif2alpha(+/-)) mice after exposure to 10% O(2) for 4 weeks. In contrast to WT mice, Hif2alpha(+/-) mice were fully protected against pulmonary hypertension and right ventricular hypertrophy, unveiling a critical role of HIF-2alpha in hypoxia-induced pulmonary vascular remodeling. Pulmonary expression levels of endothelin-1 and plasma catecholamine levels were increased threefold and 12-fold respectively in WT but not in Hif2alpha(+/-) mice after hypoxia, suggesting that HIF-2alpha-mediated upregulation of these vasoconstrictors contributes to the development of hypoxic pulmonary vascular remodeling.

MeSH Terms
Animals Atmosphere Exposure Chambers Basic Helix-Loop-Helix Transcription Factors Catecholamines/blood Endothelin-1/genetics,metabolism Fetal Viability/genetics Hematocrit Heterozygote Hypertension, Pulmonary/etiology,metabolism,pathology,prevention & control Hypoxia/complications Lung/blood supply,metabolism,pathology Mice Mice, Transgenic Phenotype Pulmonary Artery/pathology RNA, Messenger/metabolism Time Trans-Activators/deficiency,genetics Up-Regulation Ventricular Dysfunction, Right/etiology,prevention & control
Chemicals
Basic Helix-Loop-Helix Transcription Factors Catecholamines Endothelin-1 RNA, Messenger Trans-Activators endothelial PAS domain-containing protein 1
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Brusselmans Koen
Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Leuven, Belgium.
Compernolle Veerle
Tjwa Marc
Wiesener Michael S
Maxwell Patrick H
Collen Désiré
Carmeliet Peter
References (45)
45 references, click to expand
  1. Mechanisms of structural remodeling in chronic pulmonary hypertension.
    Pediatr Rev. 1999 Nov;20(11):e91-e102 PMID: 10551895
  2. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses.
    Circ Res. 1999 Jun 25;84(12):1422-32 PMID: 10381895
  3. Immunohistochemical analysis of platelet-derived growth factor-B expression in myocardial tissues in hypertrophic cardiomyopathy.
    Cardiovasc Pathol. 1999 Jul-Aug;8(4):223-31 PMID: 10724527
  4. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.
    J Clin Invest. 2000 Jun;105(11):1555-62 PMID: 10841514
  5. Chronic obstructive pulmonary disease.
    N Engl J Med. 2000 Jul 27;343(4):269-80 PMID: 10911010
  6. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling.
    Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8386-91 PMID: 10880563
  7. Endothelin and pulmonary hypertension.
    J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S49-53 PMID: 10976782
  8. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?
    J Clin Invest. 2000 Sep;106(6):733-8 PMID: 10995781
  9. Suppression of tumor growth through disruption of hypoxia-inducible transcription.
    Nat Med. 2000 Dec;6(12):1335-40 PMID: 11100117
  10. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
    Circulation. 2000 Dec 5;102(23):2880-5 PMID: 11104748
  11. The NADPH oxidase inhibitors iodonium diphenyl and cadmium sulphate inhibit hypoxic pulmonary vasoconstriction in isolated rat pulmonary arteries.
    Physiol Res. 2000;49(5):587-96 PMID: 11191363
  12. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment.
    Respir Med. 2000 Dec;94(12):1221-8 PMID: 11192959
  13. Pulmonary hypertension in COPD: old and new concepts.
    Monaldi Arch Chest Dis. 2000 Dec;55(6):445-9 PMID: 11272628
  14. Extrapulmonary effects of chronic obstructive pulmonary disease.
    Curr Opin Pulm Med. 2001 Mar;7(2):84-92 PMID: 11224729
  15. Nitric oxide production in the hypoxic lung.
    Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L575-82 PMID: 11237994
  16. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
    Circulation. 2001 Apr 17;103(15):2014-20 PMID: 11306532
  17. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
    Nat Med. 2001 May;7(5):575-83 PMID: 11329059
  18. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia.
    Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L202-8 PMID: 11404263
  19. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.
    Am J Respir Crit Care Med. 2001 Jul 15;164(2):314-8 PMID: 11463607
  20. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling.
    Am J Respir Cell Mol Biol. 2001 Jul;25(1):104-10 PMID: 11472982
  21. Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia.
    J Biol Chem. 2001 Oct 19;276(42):39192-6 PMID: 11546756
  22. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension.
    Circulation. 2001 Oct 30;104(18):2242-8 PMID: 11684638
  23. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management.
    Respirology. 2002 Mar;7(1):3-13 PMID: 11896895
  24. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.
    Nat Med. 2002 Jul;8(7):702-10 PMID: 12053176
  25. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.
    FASEB J. 2003 Feb;17(2):271-3 PMID: 12490539
  26. Increased circulating plasma norepinephrine concentrations in noncardiac causes of pulmonary hypertension.
    Crit Care Med. 1984 Feb;12(2):85-9 PMID: 6697736
  27. The response of microvessels in rat lung explants to incubation with norepinephrine.
    Exp Lung Res. 1984;7(2):93-100 PMID: 6525985
  28. Alpha 1-adrenergic stimulation and beta 2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells.
    Mol Pharmacol. 1990 Jan;37(1):30-6 PMID: 2153907
  29. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.
    Circ Res. 1991 Jul;69(1):209-15 PMID: 2054934
  30. Inositol trisphosphate is involved in norepinephrine- but not in hypoxia-induced pulmonary arterial contraction.
    Am J Physiol. 1993 Feb;264(2 Pt 1):L160-4 PMID: 8447428
  31. Nitric oxide synthases: roles, tolls, and controls.
    Cell. 1994 Sep 23;78(6):915-8 PMID: 7522969
  32. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat.
    Circ Res. 1995 Feb;76(2):215-22 PMID: 7834832
  33. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.
    Genes Dev. 1997 Jan 1;11(1):72-82 PMID: 9000051
  34. Cellular and molecular mechanisms of pulmonary vascular remodeling.
    Annu Rev Physiol. 1997;59:89-144 PMID: 9074758
  35. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development.
    Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4273-8 PMID: 9113979
  36. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels.
    Mech Dev. 1997 Apr;63(1):51-60 PMID: 9178256
  37. Pharmacological strategies for improving diastolic dysfunction in the setting of chronic pulmonary hypertension.
    Circulation. 1998 Apr 28;97(16):1606-12 PMID: 9593566
  38. Vascular development and disorders: molecular analysis and pathogenic insights.
    Kidney Int. 1998 Jun;53(6):1519-49 PMID: 9607184
  39. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3.
    J Clin Invest. 1998 Jun 1;101(11):2468-77 PMID: 9616218
  40. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.
    Nature. 1998 Jul 30;394(6692):485-90 PMID: 9697772
  41. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development.
    Genes Dev. 1998 Nov 1;12(21):3320-4 PMID: 9808618
  42. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia.
    J Clin Invest. 1999 Jan;103(2):291-9 PMID: 9916141
  43. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.
    J Clin Invest. 1999 Mar;103(5):691-6 PMID: 10074486
  44. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension.
    J Clin Invest. 1999 Jun;103(11):1509-15 PMID: 10359560
  45. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.
    Annu Rev Cell Dev Biol. 1999;15:551-78 PMID: 10611972
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2003-05-00
Pages
1519-27
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC155039
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]